API | clivatuzumab tetraxetan

clivatuzumab tetraxetan Report issue

Biologics mAb ADC Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Yttrium (90Y) clivatuzumab tetraxetan is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

yttrium y 90 clivatuzumab tetraxetan

hupam4

clivatuzumab tetraxetan

More Chemistry

Pharmacology

Mechanisms of Action:
- Mucin-1 (Homo sapiens) ^UniProt
- Mucin-5AC (Homo sapiens) ^UniProt
- Mucin-1 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: 90-Yttrium
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Pancreatic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue